Biotin Lab-Test Interference — The Most Underappreciated Supplement Safety Issue in Clinical Practice

A patient takes a 10,000 mcg biotin gummy each morning for thicker hair. Two months later, she presents to her doctor with palpitations and her TSH comes back undetectable with elevated free T4 — a textbook pattern of Graves' disease. She undergoes radioactive iodine ablation. Her thyroid was completely normal. The pattern she presented with was an artifact of biotin interfering with the streptavidin-biotin chemistry that drives most modern immunoassays. The FDA has issued two formal safety communications about this. At least one death has been linked to a missed myocardial infarction because biotin falsely lowered a troponin reading. This is the single most clinically important fact about biotin supplementation and the one that consumers, supplement manufacturers, and many clinicians are least aware of. This page explains the mechanism, walks through every category of test affected, lays out the FDA guidance, and gives the practical washout-period protocol every biotin user must know.

Table of Contents

1. The Scale of the Problem
2. The Mechanism — Why Biotin Breaks Immunoassays
3. Thyroid — The Graves' Disease Mimic
4. Troponin — The Missed Heart Attack
5. hCG — The Missed Ectopic Pregnancy
6. Hormone Panels — Cortisol, PTH, Sex Hormones
7. Tumor Markers — PSA, CA-125, AFP
8. 25(OH)D, Ferritin, and Other Routine Tests
9. The FDA 2017 and 2019 Safety Communications
10. Washout Periods — What to Actually Do
11. High-Risk Scenarios Every Patient Should Know
12. Assay Manufacturers' Response — Biotin-Free Platforms
13. Patient FAQ
14. Critical Cautions Summary
15. Key Research Papers
16. Connections

The Scale of the Problem

Biotin is the only common over-the-counter dietary supplement that interferes with hospital laboratory chemistry at consumer-typical doses. To understand the scale of exposure:

• Estimated 20-30% of US adults take a supplement containing biotin at any given time, most often as part of a hair-skin-nails or multivitamin product
• Typical doses in over-the-counter products: 1,000-10,000 mcg per serving — that is 33× to 333× the Adequate Intake (30 mcg/day)
• Doses used in MS clinical trials and protocols: 300,000 mcg (300 mg) per day — 10,000× the AI
• Streptavidin-biotin immunoassay technology is used by most major hospital laboratory analyzer platforms (Roche, Abbott, Siemens, Beckman, Ortho) and underlies hundreds of distinct clinical tests
• Therefore: at any given moment, tens of millions of Americans are circulating supplement-derived biotin at concentrations capable of distorting their next hospital lab test

The clinically significant cases — misdiagnoses leading to inappropriate treatment, or correct diagnoses missed because the lab read normal — are by definition under-counted because they typically come to light only when a careful clinician retrospectively connects the dots. The published literature contains hundreds of case reports; the true frequency is unknown and almost certainly much higher.

Back to Table of Contents

The Mechanism — Why Biotin Breaks Immunoassays

To understand the interference, you have to understand how modern automated immunoassays work. Most hospital laboratories run two designs:

Sandwich (immunometric) assay — used for hormones with large molecules: TSH, hCG, PTH, troponin, tumor markers

1. A capture antibody is conjugated to biotin. It is added to the patient's blood sample.
2. Patient analyte (e.g., TSH) binds the capture antibody.
3. A detection antibody — conjugated to a signal-generating molecule (chemiluminescent, fluorescent, enzyme) — binds a different epitope on the same analyte.
4. The mixture is then exposed to a streptavidin-coated solid phase (a magnetic bead, a microwell, etc.). Streptavidin is a protein with extremely high affinity for biotin (Kd ~10^-15 M, one of the strongest non-covalent bonds in biology). The streptavidin captures the biotinylated antibody (with the analyte and detection antibody attached), pulls it out of solution, and the signal is read.
5. Signal intensity is proportional to analyte concentration. More analyte = more captured sandwich = higher signal.

If the patient has free biotin circulating in their blood, that biotin competes with the biotinylated capture antibody for streptavidin binding sites. Some of the streptavidin sites are occupied by free biotin instead of the capture-antibody complex. The complex is washed away. Signal is artificially reduced. The assay reads falsely LOW.

Competitive assay — used for small molecules: T4, T3, cortisol, sex hormones, 25(OH)D

1. A biotinylated analyte analog competes with the patient's actual analyte for a limited number of detection-antibody binding sites.
2. The streptavidin solid phase captures both bound and unbound biotinylated analog.
3. Signal is generated only by the bound detection antibody. More patient analyte = less analog captured = LESS signal. The relationship is inverse.

If the patient has free biotin, it again competes with the biotinylated analog for streptavidin. The biotinylated analog is washed away. Less analog is captured. The assay reads as if there is more patient analyte present. The assay reads falsely HIGH.

Net effect across both assay types:

• Sandwich assays (TSH, hCG, PTH, troponin, tumor markers) — biotin causes FALSELY LOW results
• Competitive assays (T4, T3, cortisol, testosterone, estradiol, 25(OH)D) — biotin causes FALSELY HIGH results

This is why biotin interference on a thyroid panel produces the exact pattern of Graves' disease: TSH (sandwich assay) reads falsely LOW + free T4 (competitive assay) reads falsely HIGH. The endocrine pattern looks identical to true hyperthyroidism.

Back to Table of Contents

Thyroid — The Graves' Disease Mimic

Thyroid function testing is the most commonly affected by biotin interference because (a) thyroid panels are among the most frequently ordered tests in medicine, and (b) the pattern of interference perfectly mimics the most aggressive form of hyperthyroidism.

The pattern

• TSH: undetectable or very low (false — sandwich assay reads low)
• Free T4: high or very high (false — competitive assay reads high)
• Free T3: high or very high (false — competitive assay reads high)
• TSH receptor antibody (TRAb): correctly negative (this assay uses different chemistry and is not affected)
• Patient is asymptomatic or has only mild non-specific symptoms (mild anxiety, palpitations from caffeine, etc.)

What goes wrong clinically

The classic case — reported in many published series including Kummer 2016 in NEJM, Barbesino 2016, and dozens of subsequent reports — is a young or middle-aged woman taking a hair-and-nails biotin supplement (5,000-10,000 mcg/day) who has thyroid testing for any reason. The test returns the Graves'-mimicking pattern. The patient is referred to endocrinology. Without anyone asking about supplements, the endocrinologist might:

• Start methimazole (antithyroid drug) — will cause hypothyroidism if continued
• Order a radioiodine uptake scan — will be normal (which is the first clue that something is off)
• If the scan is misread or skipped, recommend radioactive iodine ablation — an irreversible destruction of the thyroid gland leaving the patient hypothyroid for life and requiring lifelong levothyroxine replacement

The literature contains multiple cases where patients received inappropriate antithyroid drugs, inappropriate beta-blockers, inappropriate workup for thyroid storm, and in the most extreme reports inappropriate thyroid ablation, all because the biotin in their hair supplement was creating a Graves'-mimicking lab pattern.

The fix

The negative TSH receptor antibody (TRAb) is the diagnostic clue — true autoimmune Graves' disease is TRAb-positive in ~95% of cases. If TSH is suppressed and free T4 is elevated but TRAb is negative, biotin interference must be on the differential. Stop biotin, retest in 5-7 days, and the panel normalizes. This pattern has been published so many times that it should now be reflexively checked in any new "subclinical hyperthyroidism" picked up in a routine panel.

Back to Table of Contents

Troponin — The Missed Heart Attack

Cardiac troponin (cTnT, cTnI) is the gold-standard biomarker for myocardial injury. A patient presenting to the emergency department with chest pain receives serial troponin measurements; if elevated, the diagnosis is acute myocardial infarction and the patient is admitted, anticoagulated, and goes to the catheterization lab. If serial troponins remain normal, the patient is discharged.

Troponin is measured by sandwich immunoassay. Biotin interference produces falsely low troponin. This means a patient on high-dose biotin who is actually having a heart attack can present with normal-appearing troponins, leading to discharge from the ED with the catastrophic outcome the test was designed to prevent.

The FDA 2019 safety communication update was specifically prompted by a death linked to this exact scenario — a patient on high-dose biotin (in the MS-trial context) whose troponin read falsely low, leading to a missed acute MI and a fatal outcome. The FDA called this out by name as an avoidable death.

For any patient on biotin presenting with chest pain or any symptom that might prompt troponin measurement:

• Tell the ED triage nurse you take biotin — before any blood draw
• Specify the dose and last administration time
• The lab can run an alternative troponin platform (some assays are biotin-resistant) or a different cardiac biomarker (CK-MB has been around longer and is not biotin-vulnerable)
• Serial measurements with the lab informed of the biotin exposure allow the clinician to track troponin dynamics even with an absolute bias in the level

Back to Table of Contents

hCG — The Missed Ectopic Pregnancy

Quantitative beta-hCG measurement is used to confirm pregnancy, follow early pregnancy viability (the 48-hour doubling rule), diagnose ectopic pregnancy, monitor gestational trophoblastic disease, and detect certain tumors. It is a sandwich immunoassay. Biotin produces falsely low hCG.

The clinically dangerous scenario: a woman of reproductive age on biotin presents with abdominal pain and missed menses. Her quantitative beta-hCG returns low (or undetectable). She is told she is not pregnant. The actual diagnosis is ectopic pregnancy. The delay in correct diagnosis can be measured in hours that determine whether the patient experiences tubal rupture, hemorrhage, and emergency surgery vs medical management with methotrexate.

Published case reports (Mzougui and colleagues, others) document exactly this scenario. Any woman of reproductive age on biotin who presents with acute abdominal symptoms must have biotin interference on the differential when hCG returns surprisingly low.

Back to Table of Contents

Hormone Panels — Cortisol, PTH, Sex Hormones

Endocrine workups span both sandwich (PTH, ACTH, anti-TPO, anti-Tg) and competitive (cortisol, testosterone, estradiol, DHEA-S, progesterone) assays. Biotin distorts both. Specific scenarios:

• Parathyroid hormone (PTH): sandwich assay — falsely low. A patient on high-dose biotin with hypercalcemia and a low PTH might appear to have non-PTH-mediated hypercalcemia (malignancy workup triggered) when the real picture was primary hyperparathyroidism.
• Cortisol: competitive assay — falsely high. Can mimic Cushing's syndrome.
• ACTH: sandwich assay — falsely low. Combined with falsely high cortisol, mimics adrenal Cushing's.
• Testosterone, estradiol, DHEA-S: competitive assays — falsely high. Can falsely suggest androgen-secreting tumors or hyperandrogenism.
• Anti-thyroid peroxidase, anti-thyroglobulin: sandwich — falsely low. Can falsely "rule out" autoimmune thyroiditis.
• 25-hydroxyvitamin D: competitive — falsely high. A patient with actual vitamin D deficiency may have her supplementation discontinued because the level reads normal-high.
• Aldosterone, renin: can be affected on some platforms; primary aldosteronism workups can be distorted.

Any endocrinology consultation in a biotin user requires that the consultant know about the biotin first.

Back to Table of Contents

Tumor Markers — PSA, CA-125, AFP

Tumor markers are usually sandwich assays. Biotin produces falsely low results.

• PSA (prostate specific antigen): Falsely low. A man on biotin with rising PSA from prostate cancer can have his PSA read normal, delaying biopsy and diagnosis.
• CA-125 (ovarian cancer marker): Falsely low. A woman on biotin with recurrent ovarian cancer can have monitoring CA-125 read normal during active recurrence.
• AFP (alpha-fetoprotein): Falsely low. Both hepatocellular carcinoma surveillance and germ-cell tumor monitoring are affected. Prenatal screening for neural tube defects uses AFP and is similarly affected.
• CEA, CA 19-9, beta-2 microglobulin, thyroglobulin: All sandwich assays. All falsely low.

The thyroglobulin issue is especially poignant: patients with treated thyroid cancer are monitored for recurrence with serial thyroglobulin measurements. Falsely low thyroglobulin from biotin masks recurrence. A patient taking biotin for hair growth might have her recurrence missed for a full cycle of monitoring, allowing the disease to progress further before correct detection.

Back to Table of Contents

25(OH)D, Ferritin, and Other Routine Tests

The interference is not limited to high-stakes hospital tests. Routine outpatient labs are also affected:

• 25(OH)D: typically competitive assay — falsely high. The vitamin D status of a biotin user is likely systematically overestimated.
• Ferritin: sandwich assay on most platforms — falsely low. A patient with iron deficiency may have her ferritin look more abnormal than it is (often clinically irrelevant since low ferritin is already abnormal, but the magnitude can be off).
• B12 and folate: competitive on most platforms — falsely high. A B12-deficient patient on biotin may have her B12 deficiency masked.
• Free testosterone (calculated from total testosterone + SHBG): total testosterone competitive assay falsely high, SHBG sandwich falsely low — the calculated free testosterone is doubly elevated.
• Insulin: sandwich on most platforms — falsely low. Can affect insulin resistance assessment, HOMA-IR calculation.
• C-peptide: sandwich — falsely low. Type 1 vs type 2 diabetes classification can be affected.
• Anti-HIV, anti-HCV serologies on some platforms: can be affected, with false negatives reported in case literature.

Glucose, basic electrolytes, blood counts, and most chemistries are NOT immunoassay-based and are unaffected.

Back to Table of Contents

The FDA 2017 and 2019 Safety Communications

November 2017 communication

The FDA issued its first formal safety communication titled "The FDA Warns that Biotin May Interfere with Lab Tests." The communication acknowledged that biotin was an underrecognized cause of incorrect lab results, identified the streptavidin-biotin assay mechanism, listed affected test categories (especially thyroid and troponin), and recommended that patients inform their healthcare providers about biotin use.

November 2019 update

The FDA reissued and expanded the communication, explicitly citing a reported death linked to falsely low troponin in a patient on high-dose biotin. The 2019 update emphasized:

• The interference is real, clinically significant, and potentially fatal
• Patients on high-dose biotin (commonly 5,000-10,000 mcg/day for cosmetic purposes; 300,000 mcg/day in MS trials) are at highest risk
• Healthcare providers should ask about biotin use before ordering any immunoassay-based test
• Laboratory directors should know which of their assay platforms are biotin-vulnerable
• Assay manufacturers should redesign platforms to be biotin-resistant

The communication did not lead to any regulatory action against biotin supplements themselves (which remain regulated as dietary supplements under DSHEA, with no safety review requirement). Consumer-side awareness remains low.

Back to Table of Contents

Washout Periods — What to Actually Do

Biotin elimination follows first-order pharmacokinetics. Half-life is approximately 1.8 hours after oral dosing. Practical washout periods to drop biotin below the assay-interference threshold:

Critical caveats:

• The "minimum washout" is generally sufficient for most assays but does NOT guarantee zero interference on every platform — especially for the most sensitive sandwich assays (TSH, troponin, hCG)
• Patients with reduced renal function clear biotin more slowly — double the washout times
• For high-stakes tests (suspected acute MI, suspected ectopic pregnancy, tumor recurrence monitoring), prefer the "safer washout" duration
• For acute presentations where waiting is not possible (chest pain in the ED), the lab can run a biotin-free assay platform or use a different biomarker

Back to Table of Contents

High-Risk Scenarios Every Patient Should Know

Stop biotin and inform the clinician about your usual dose if any of the following situations are imminent:

• Annual physical with routine labs — even basic thyroid panels on the standard panel will be affected. Discontinue 5-7 days before the appointment for typical 5,000-10,000 mcg consumer doses.
• Endocrinology consultation — thyroid, parathyroid, adrenal, pituitary, or reproductive endocrine workup. All hormone panels are at risk. Tell the endocrinologist about biotin at the first visit, before any tests are ordered.
• Cardiology workup — especially anything where troponin or NT-proBNP might be measured. Tell every clinician.
• Oncology surveillance — PSA monitoring, CA-125, thyroglobulin, CEA, AFP. Falsely-low tumor markers can delay recurrence detection.
• OB/GYN visit during pregnancy planning or early pregnancy — hCG can be affected. If you might be pregnant, stop biotin and tell the clinician.
• Any emergency department visit — tell the triage nurse and the ED physician about biotin before any blood draw. Acute MI, ectopic pregnancy, hypercalcemic crisis, adrenal crisis — all have potential biotin interference.
• Pre-operative bloodwork — if you are scheduled for any surgery requiring labs, stop biotin a week before.
• Pediatric workup for inborn errors of metabolism — while paradoxical (biotinidase deficiency itself is detected by a different mechanism), other inborn-error panels can be affected.
• Doping control in athletes — some doping panels use immunoassay screening and can be affected, although confirmatory mass spectrometry is biotin-resistant.

Back to Table of Contents

Assay Manufacturers' Response — Biotin-Free Platforms

Following the FDA communications, major assay manufacturers (Roche, Abbott, Siemens, Beckman) have been redesigning their assay chemistries to reduce or eliminate biotin susceptibility. Strategies include:

• Higher-affinity capture reagents — using novel streptavidin variants or alternative binding chemistries with affinities such that physiologic biotin concentrations cannot displace the capture antibody
• Biotin scavenging — pre-treating samples with reagents that bind free biotin before the assay runs
• Higher biotin tolerance thresholds — raising the assay-specific tolerable biotin concentration from ~30 ng/mL (a level easily exceeded by 5 mg biotin supplements) to 1,200 ng/mL or higher
• Non-biotinylated alternative chemistries — some next-generation assays avoid streptavidin-biotin entirely

Progress has been real but uneven. As of 2026, most labs have a mix of biotin-vulnerable and biotin-resistant platforms. The vulnerability is platform- and analyte-specific. Patients should not assume the issue is solved. The safe approach remains: hold biotin before bloodwork, inform every clinician.

Back to Table of Contents

Patient FAQ

Q: I take a 5,000 mcg biotin gummy daily for my hair. Should I be worried?
Yes, in the sense that you should be informed and you should hold the supplement 5-7 days before any bloodwork. Your daily 5 mg dose is high enough to interfere with multiple assays. Most days, this will never matter. But the day you present to the ED with chest pain or the day your doctor checks a routine thyroid panel, it could matter a great deal.

Q: My biotin bottle doesn't mention this risk. Is that legal?
Yes. Dietary supplements in the US are regulated under DSHEA and are not required to carry the kinds of safety warnings that pharmaceuticals carry. The FDA has communicated about biotin interference but has not mandated label warnings on the supplements themselves. Some manufacturers have voluntarily added warnings; most have not.

Q: Will the lab tell my doctor about possible biotin interference?
Generally only if the result is so far out of range that it triggers an automatic comment. Most lab reports do not flag biotin interference. The responsibility falls on the patient and the clinician to ask.

Q: I am about to have surgery. When should I stop my biotin?
At least 7 days before for typical 5,000-10,000 mcg doses. 14-21 days for MS-protocol doses (300 mg). Mention it to the anesthesiologist and surgeon at the pre-op visit.

Q: Is the biotin in my B-complex multivitamin enough to interfere?
Probably not at low doses (30-300 mcg). The interference threshold for most modern assays is in the 30-100 ng/mL serum biotin range, which is exceeded by single doses around 1,000 mcg or more taken within the prior 24-48 hours. Standard multivitamin doses (30-300 mcg) are unlikely to cause clinically meaningful interference. But standalone biotin products (1,000+ mcg) and hair-skin-nail combos (5,000+ mcg) definitely can.

Q: I am on 300 mg/day biotin for multiple sclerosis. Is bloodwork ever interpretable?
Only if specifically planned. The clinician must know about the 300 mg dose, must choose biotin-resistant assay platforms when available, and may need to use alternative biomarkers (CK-MB instead of troponin, urinary cortisol instead of serum cortisol, etc.) for critical assessments. See the High-Dose MS Trials page for context — this dose is no longer recommended for routine MS care.

Q: What is the safest dose if I want to take biotin?
For most adults, dietary biotin (eggs, nuts, salmon) provides far more than the 30 mcg AI. Supplemental biotin at the doses found in standard multivitamins (30-300 mcg) is unlikely to interfere with labs. Doses above 1 mg should be reserved for documented medical indications, not cosmetic use.

Back to Table of Contents

Critical Cautions Summary

• Tell every clinician, every visit. Spontaneously volunteer biotin use at every healthcare encounter. Do not wait to be asked. Specify dose and frequency.
• Default washout for routine bloodwork: 5 days. For consumer-dose biotin (5,000-10,000 mcg/day), 5 days off is a reasonable default. For 300 mg MS-protocol doses, 14+ days.
• The Graves' mimic pattern is biotin until proven otherwise in a biotin user. Suppressed TSH + elevated free T4 in any patient on biotin requires repeat after washout before any treatment is started. TRAb negativity is a major clue.
• In acute chest pain on biotin: tell the ED. Falsely-low troponin can be lethal. The lab can run an alternative platform or alternative biomarker (CK-MB) if alerted.
• In acute abdominal pain in a woman on biotin: hCG may be falsely low. Ectopic pregnancy can be missed. Tell the ED.
• Falsely-low tumor markers can mask cancer recurrence. Patients on cancer surveillance who take biotin can have their recurrence go undetected for a monitoring cycle. Discontinue biotin before tumor-marker draws.
• Falsely-low PTH masks primary hyperparathyroidism. Hypercalcemia + low PTH on a biotin user may actually be PTH-driven hyperparathyroidism.
• Falsely-high cortisol mimics Cushing's. Workups for Cushing's in biotin users must be done off biotin.
• Even competitive-assay false ELEVATIONS can cause harm. Falsely-high 25(OH)D can lead to discontinuation of needed vitamin D supplementation. Falsely-high testosterone can prompt unnecessary tumor workup.
• Biotin in MS protocols (300 mg/day) is no longer evidence-supported. The original Tourbah 2016 positive signal did not replicate in the SPI2 2020 confirmatory trial. See the High-Dose MS Trials page. Patients still on this dose should discuss discontinuation with their neurologist.
• Cosmetic biotin (5,000-10,000 mcg) has essentially no RCT evidence for benefit in non-deficient adults. See the Hair, Skin & Nails page. Weigh the unproven benefit against the documented lab-interference risk.

Back to Table of Contents

Key Research Papers

1. FDA (2017). The FDA Warns that Biotin May Interfere with Lab Tests: FDA Safety Communication. — PubMed
2. FDA (2019). Update: The FDA Warns that Biotin May Interfere with Lab Tests — Death Reported. — PubMed
3. Kummer S, Hermsen D, Distelmaier F (2016). Biotin Treatment Mimicking Graves' Disease. New England Journal of Medicine. — PubMed
4. Barbesino G (2016). Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses. Thyroid. — PubMed
5. Piketty ML et al. (2017). High-dose biotin therapy leading to false biochemical endocrine profiles. European Journal of Endocrinology. — PubMed
6. Trambas C et al. (2018). The case for biotin interference: how the assay works and why it matters. Pathology. — PubMed
7. Holmes EW et al. (2017). Biotin Interference in Clinical Immunoassays: A Cause for Concern. Archives of Pathology & Laboratory Medicine. — PubMed
8. Li D, Radulescu A, Shrestha RT et al. (2017). Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA. — PubMed
9. Samarasinghe S et al. (2017). Biotin interference with routine clinical immunoassays: understand the causes and mitigate the risks. Endocrine Practice. — PubMed
10. Avery G (2019). Biotin interference in immunoassay: a review for the laboratory scientist. Annals of Clinical Biochemistry. — PubMed
11. Ali M et al. (2020). The continuing concern of biotin interference in immunoassay: redesigning assays to mitigate. Clinica Chimica Acta. — PubMed
12. Bowen R et al. (2019). Biotin Interference with 25-Hydroxyvitamin D Immunoassay. Journal of Applied Laboratory Medicine. — PubMed

PubMed Topic Searches

• PubMed: biotin immunoassay interference
• PubMed: biotin thyroid test interference
• PubMed: biotin troponin false negative
• PubMed: biotin hCG interference
• PubMed: streptavidin biotin assay platforms

Back to Table of Contents

Connections

• Vitamin B7 Overview
• Benefits Hub
• Hair, Skin & Nails
• Multiple Carboxylase Deficiency
• High-Dose MS Trials
• Graves' Disease
• Hashimoto's Thyroiditis
• Hyperthyroidism
• Hypothyroidism
• Heart Attack (MI)
• Multiple Sclerosis
• TSH
• Free T4
• 25(OH)D (Vitamin D)
• Ferritin
• PSA
• Cortisol
• Troponin
• All Vitamins

Back to Table of Contents